J&J's drug features a silicone-based drug delivery system that allows for the continuous release of gemcitabine chemotherapy and is administered into the bladder via a catheter. The FDA has ...

(UroToday.com) The 2025 SESAUA annual meeting featured a bladder cancer session and a presentation by Dr. Peter Clark discussing a first-in-human study of TAR-210 erdafitinib intravesical system in ...

Hero MotoCorp's new XPulse 210 motorcycle, with its advanced design, revamped features, and a 210cc engine, offers significant performance and comfort improvements over its predecessor.

The new Hero Xpulse 210 is a hot topic — it gets a bigger heart. The Xpulse platform has been a great beginner’s motorcycle but for the experienced, the motorcycle lacked grunt, especially out ...

Two big launches were Xpulse 210 and Xtreme 250R, both of them new entrants to the Hero’s Premia range. Initially bookings were supposed to open in February 2025, however, for unknown reasons ...

IRWINDALE, Calif. (KABC) -- Dashcam video captured a terrifying motorcycle crash Tuesday on the Eastbound 210 Freeway in Irwindale, according to the California ...

Following after in J&J's Taris-derived pipeline is TAR-210, an intravesical formulation of J&J's FGFR kinase inhibitor Balversa (erdafitinib), which started the phase 3 MoonRISe-1 trial in ...

LAKE CHARLES, La. (KPLC) - After it was damaged in the 2020 storms, the lighting system on the 210 bridge was scheduled to be completed in June 2022, but was delayed. “One of the reasons it was ...

The Boston College Eagles (10-11, 3-6 ACC) baseball team lost its rubber match to the No. 17 UNC Tar Heels (18-6, 4-5 ACC) 10-0 on Sunday afternoon. After losing the series opener 5-1 and ...

Hero MotoCorp has revealed that bookings for the XPulse 210 and the Xtreme 250R will begin from March 20, 2025. Both the bikes were launched at Bharat Mobility Expo 2025. Hero had initially ...

Additionally, the Phase 3 MoonRISe-1 (BLC3004, NCT06319820) study is assessing TAR-210 compared to single-agent intravesical chemotherapy in patients with intermediate-risk non-muscle invasive ...